Imatinib mesylate induced skin hypopigmentation.
Talwar
V
V
Doval
D C
DC
Bhatia
Komal
K
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D016313:Genes, abl / Q000187:drug effects; D006801:Humans; D017496:Hypopigmentation / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases